What is the price target for ADMA biologics (ADMA)?
- ADMA Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis Adma Biologics Stock Forecast, ADMA stock price prediction. Price target in 14 days: 1.433 USD.
What is the upside for ADMA Biologics'stock?
Their forecasts range from $3.00 to $10.00. On average, they anticipate ADMA Biologics' stock price to reach $5.70 in the next twelve months. This suggests a possible upside of 328.6% from the stock's current price. View analysts' price targets for ADMA Biologics or view top-rated stocks among Wall Street analysts.
Where can I buy shares of ADMA?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is the ADMA biomanufacturing segment?
The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses.
Is ADMA Biologics a good stock to buy?
ADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Will ADMA go up?
The 2 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 4.75, with a high estimate of 5.00 and a low estimate of 4.50. The median estimate represents a +113.96% increase from the last price of 2.22.
Who owns ADMA Biologics?
Adam S. Grossman FounderAdam S. Grossman Founder, Director, President & Chief Executive Officer. Mr. Grossman has been the driving force behind ADMA Biologics' mission to develop and bring to market novel plasma derived products to address certain unmet medical needs for immune compromised patients.
Is ADMA undervalued?
Significantly Below Fair Value: ADMA is trading below fair value by more than 20%.
Why is ADMA a buy?
The ADMA Biologics Inc stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
When did ADMA go public?
The company's shares are expected to begin trading on The OTCQB Marketplace on October 17, 2013 under the ticker symbol “ADMA.” The offering is expected to close on October 22, 2013, subject to customary closing conditions.
What does ADMA stand for?
Asymmetric dimethylarginine (ADMA) is a marker of endothelial dysfunction that could contribute to increased cardiovascular risk in patients with PA.
What does ADMA make?
ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection.
Where is ADMA Biologics located?
N.W. Boca Raton, FLAll of our contract manufacturing is performed at our fractionation facility located at 5800 Park of Commerce Blvd., N.W. Boca Raton, FL 33487. Fully cGMP compliant plasma processing facility and lab located in Boca Raton, Florida.
Should I buy or sell ADMA Biologics stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 4 buy rating...
What is ADMA Biologics' stock price forecast for 2022?
5 analysts have issued twelve-month price objectives for ADMA Biologics' stock. Their forecasts range from $3.00 to $10.00. On average, they expect...
How has ADMA Biologics' stock performed in 2022?
ADMA Biologics' stock was trading at $1.41 at the beginning of 2022. Since then, ADMA shares have increased by 37.6% and is now trading at $1.94....
When is ADMA Biologics' next earnings date?
ADMA Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for ADM...
How were ADMA Biologics' earnings last quarter?
ADMA Biologics, Inc. (NASDAQ:ADMA) posted its quarterly earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.10) earnin...
What guidance has ADMA Biologics issued on next quarter's earnings?
ADMA Biologics issued an update on its FY 2022 earnings guidance on Wednesday, June, 8th. The company provided EPS guidance of for the period. The...
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the following people: Mr. Adam S. Grossman , Co-Founder, Pres, CEO & Director (Age 45, Pay $1.13M) ( Li...
What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?
9 employees have rated ADMA Biologics CEO Adam S. Grossman on Glassdoor.com . Adam S. Grossman has an approval rating of 29% among ADMA Biologics'...
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Twist Bioscience (TWST) , Krystal Biotech (KRYS) , Allogene Therapeutics (ALLO) , Imm...
About ADMA Biologics
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.
